BACKGROUND AND PURPOSE: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Histone deacetylase inhibitors (HDACi), a new class of anti-cancer agents, have recently been reported to exhibit potent anti-inflammatory activities. A proof of concept study was carried out with suberoylanilide hydroxamic acid (SAHA) and MS-275, two HDACi currently undergoing clinical investigations for various oncological indications. EXPERIMENTAL APPROACH: The anti-rheumatic effects of SAHA and MS-275 were assessed in both mouse and rat collagen induced arthritis (CIA) models. KEY RESULTS: SAHA exhibited moderate prophylactic efficacy. It attenuated paw swelling due to inflammation, decreased bone erosion in both mice and rats and reduced slightly the RA-induced bone resorption in rats. However, SAHA could not inhibit the onset of arthritis. In contrast, MS-275 displayed dramatic anti-rheumatic activities. In prophylactic intervention, high doses of MS-275 prevented bone erosion and markedly delayed the onset of arthritis; at low doses, MS-275 strongly attenuated paw swelling, bone erosion, and bone resorption associated with RA. Furthermore, the therapeutic efficacy of MS-275 was also documented. After the onset of arthritis, it could stop the disease progression and joint destruction. An anti inflammatory effect of MS-275 was also confirmed through its capacity to decrease serum IL-6 and IL-1beta levels in the CIA induced mouse model. The anti-rheumatic activity of MS-275 was also confirmed through histological observation. No synovial hyperplasia, pannus formation, cartilage or bone destruction were observed in the high dose prophylactic intervention in mice. CONCLUSION AND IMPLICATION: This study strongly supported HDACi as an innovative therapeutic strategy for RA.
BACKGROUND AND PURPOSE:Rheumatoid arthritis (RA) is a chronic inflammatory disease. Histone deacetylase inhibitors (HDACi), a new class of anti-cancer agents, have recently been reported to exhibit potent anti-inflammatory activities. A proof of concept study was carried out with suberoylanilide hydroxamic acid (SAHA) and MS-275, two HDACi currently undergoing clinical investigations for various oncological indications. EXPERIMENTAL APPROACH: The anti-rheumatic effects of SAHA and MS-275 were assessed in both mouse and rat collagen induced arthritis (CIA) models. KEY RESULTS:SAHA exhibited moderate prophylactic efficacy. It attenuated paw swelling due to inflammation, decreased bone erosion in both mice and rats and reduced slightly the RA-induced bone resorption in rats. However, SAHA could not inhibit the onset of arthritis. In contrast, MS-275 displayed dramatic anti-rheumatic activities. In prophylactic intervention, high doses of MS-275 prevented bone erosion and markedly delayed the onset of arthritis; at low doses, MS-275 strongly attenuated paw swelling, bone erosion, and bone resorption associated with RA. Furthermore, the therapeutic efficacy of MS-275 was also documented. After the onset of arthritis, it could stop the disease progression and joint destruction. An anti inflammatory effect of MS-275 was also confirmed through its capacity to decrease serum IL-6 and IL-1beta levels in the CIA induced mouse model. The anti-rheumatic activity of MS-275 was also confirmed through histological observation. No synovial hyperplasia, pannus formation, cartilage or bone destruction were observed in the high dose prophylactic intervention in mice. CONCLUSION AND IMPLICATION: This study strongly supported HDACi as an innovative therapeutic strategy for RA.
Authors: Flavio Leoni; Andrea Zaliani; Giorgio Bertolini; Giulia Porro; Paolo Pagani; Pietro Pozzi; Giancarlo Donà; Gianluca Fossati; Silvano Sozzani; Tania Azam; Philip Bufler; Giamila Fantuzzi; Igor Goncharov; Soo-Hyun Kim; Benjamin J Pomerantz; Leonid L Reznikov; Britta Siegmund; Charles A Dinarello; Paolo Mascagni Journal: Proc Natl Acad Sci U S A Date: 2002-02-26 Impact factor: 11.205
Authors: Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen Journal: Mol Med Date: 2011-01-25 Impact factor: 6.354
Authors: Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira Journal: Nat Rev Drug Discov Date: 2012-04-13 Impact factor: 84.694
Authors: M Lundh; D P Christensen; M Damgaard Nielsen; S J Richardson; M S Dahllöf; T Skovgaard; J Berthelsen; C A Dinarello; A Stevenazzi; P Mascagni; L G Grunnet; N G Morgan; T Mandrup-Poulsen Journal: Diabetologia Date: 2012-07-07 Impact factor: 10.122
Authors: Aaron M Williams; Isabel S Dennahy; Umar F Bhatti; Ben E Biesterveld; Nathan J Graham; Yongqing Li; Hasan B Alam Journal: Shock Date: 2019-09 Impact factor: 3.454
Authors: Darren M Hutt; David Herman; Ana P C Rodrigues; Sabrina Noel; Joseph M Pilewski; Jeanne Matteson; Ben Hoch; Wendy Kellner; Jeffery W Kelly; Andre Schmidt; Philip J Thomas; Yoshihiro Matsumura; William R Skach; Martina Gentzsch; John R Riordan; Eric J Sorscher; Tsukasa Okiyoneda; John R Yates; Gergely L Lukacs; Raymond A Frizzell; Gerard Manning; Joel M Gottesfeld; William E Balch Journal: Nat Chem Biol Date: 2009-12-06 Impact factor: 15.040
Authors: Rong He; Yufeng Chen; Yihua Chen; Andrei V Ougolkov; Jin-San Zhang; Doris N Savoy; Daniel D Billadeau; Alan P Kozikowski Journal: J Med Chem Date: 2010-02-11 Impact factor: 7.446